Varicose veins of lower extremities (VVs) are a common multifactorial vascular disease. 28
Varicose veins (VVs) are one of the clinical manifestations of chronic venous disease 37 posing both a cosmetic and medical problem. VVs can be found in different parts of the body, 38 but most commonly occur in the lower extremities. Prevalence estimates of this condition vary 39 across ethnic groups ranging from 2-4% in the Northern group of the Cook Islands to 50-60% in 40 some countries of the Western world 1 The cumulative evidence from epidemiological, family, and genetic association studies 52 strongly indicates that there is a hereditary component in VVs etiology [6] [7] [8] . However, despite 53 progress in this field 9-12 , current knowledge of the genetic basis of this pathology is far from 54 being complete. Elucidating genes involved in susceptibility to VVs would help to identify key 55 molecular players in the disease initiation, provide deeper insights into its pathogenesis, and 56 eventually contribute to development of improved targeted therapy aimed at VVs treating and 57 preventing. to investigate the genetics of complex traits. Today, UK Biobank is the largest repository that 60 contains information on genotypes and phenotypes for half a million participating individuals 13 . 61
This resource is open to all bona fide researchers, and access to data is provided upon approval 62 individuals and use them as a replication cohort. Data obtained in both GWAS stages were used 89 for further downstream analyses. 90
In carrying out this study, we had to face a number of challenges and limitations that must 91 be acknowledged. The first limitation was intrinsic to the general approach to phenotype 92 definition based on the electronic medical records system, which was employed in the UK 93
Biobank study. Phenotype "VVs of lower extremities" was defined based on International 94
Classification of Disease (ICD-10) billing code "I83" present in the electronic patient record. 95
The Neale Lab reported the phenotype prevalence of 2.1%. It is much lower than VVs 96 prevalence estimated by European epidemiological studies. Despite the evidence of a "healthy 97 volunteer" selection bias in the UK Biobank study 15 , such a low rate indicates that a proportion 98 of individuals remained undiagnosed. This is in line with a recent primary healthcare register-99 based study reporting VVs prevalence rate of 3% in German general practice 16 . This 100 phenomenon could be explained by a non-life-threatening nature of varicose veins, which might 101 discourage patients from communication to the doctor. Given that individuals not diagnosed with 102 I83 served as controls in our study, we could therefore expect an overall decrease in the 103 statistical power to detect gene-disease associations. Another potential source of missing 104 associations was immensely strict criteria used by the Neale Lab for single nucleotide 105 polymorphisms (SNPs) quality control removing around 75% of SNPs initially provided by UK 106 Biobank. 107 The next important limitation arose from the lack of access to individual-level data 108 resulting in the inability to control a possible selection or sampling bias. We suggested that traits 109 related to VVs risk factors could potentially cause unequal representation of patients with 110 different characteristics in the case and the control groups, and thereby induce spurious 111 associations or effect modification. The Neale Lab analyses were adjusted for sex, but other 112 factors were beyond our control. In order to address this challenge, we performed an adjustment 113 for two potential confoundersbody mass index (BMI) and deep venous thrombosis (DVT)by 114 implementation of the method based on GWAS summary statistics 17,18 (Supplementary 115 Methods). 116
Last but not least, a noteworthy debatable point in our study is the approach to generating a 117 replication cohort. Due to our intention to use only free open resources, we had to bypass the 118 need to refer to individual patient data. Our replication study sample comprised individuals who 119 have passed the Gene ATLAS quality control criteria, but have been filtered out by the Neale 120
Lab. It was almost 5 times smaller than our discovery study sample. However, although this 121 "dirty" design limited our power to replicate associations, it still could not produce any false 122 positive findings. Moreover, we calculated genetic correlations between VVs in the replication 123 cohort and VVs in both public databases to ensure that these traits are genetically similar 124
( Supplementary table 1) . VVs in our replication study was highly correlated with the same trait 125 in other datasets (rg ~ 0.9). Furthermore, it is noteworthy that VVs in the Gene ATLAS, the 126 Neale Lab as well as in BMI-and DVT-adjusted Neale Lab GWAS were almost genetically 127 equivalent (rg = 0.99 or rg = 1.00). 128 genomic inflation factor (LD Score regression intercept) λ = 1.0403. In the replication stage, 7 141 loci were replicated at P < 0.0029 (0.05/17). Manhattan plot of -log10(P) is presented in Fig.2 Regional association plots for replicated loci are given in Supplementary fig. 1 . Genes 145 located in these regions are listed in Supplementary table 2. We performed conditional and joint 146 (COJO) analysis and detected two independent signals in the locus on chromosome 16 at a 147 distance of 39 kb from each other ( Supplementary table 3 ). Lead SNPs rs9972645 and rs2911463 148 were in low linkage disequilibrium (r 2 = 0.15). 149
Functional annotation of the revealed signals 150
Literature-based annotation 151
We explored whether genes in close proximity to replicated hits could have biologically 152 plausible roles in VVs based on their functions or previously revealed associations with other 153 complex traits. The results of literature-based candidate gene prioritization are provided in Table  154 2. Furthermore, we compiled a list of traits associated at a genome-wide significance level with 155 either lead SNPs, or variants in linkage disequilibrium (LD) with these polymorphisms using 156 both the Pubmed and the PhenoScanner databases (Table 2 , Supplementary table 4 ). Our analysis 157 showed that among the genes nearest to the top GWAS loci (±250 kb), 2 genes were related to 158 vascular development and remodeling (CASZ1 and PIEZO1) with one gene having putative role 159 in vascular remodeling (STIM2), 4 genes were implicated in blood pressure and hypertension 160 (CASZ1, PIEZO1, SLC12A2, and EBF1), 2 genes were linked to inflammation (PPP3R1 and 161 EBF1), and 2 genes were ion channels involved in regulation of both cell volume and vascular 162 tone (PIEZO1 and SLC12A2). Near the SLC12A2, we identified the FBN2 gene which encodes a 163 protein regulating elastogenesis, so we prioritized both genes. 164
Two signals overlapped with findings from a recent GWAS for VVs conducted by 165 "23andMe" company 12 : rs11121615 in the CASZ1 gene, which was among the top SNPs 166 identified in that study, and rs2861819 near the PPP3R1, which was in complete LD 167 (D' = 1.00, r 2 = 0.98) with their another hit rs6712038. For 3 loci (tagged by rs2911463, 168 rs3101725, and rs7773004) a genome-wide significant association with red blood cell traits has 169 previously been demonstrated. One of these signals was near the HFE gene implicated in iron 170 absorption. The same locus showed association with height. 171
Changes in blood pressure, abnormal vascular wall remodeling, altered vascular tone, 172 deterioration of vein wall elastic properties as well as inflammation are known factors related to 173
VVs. Association with red blood cell traits is intriguing. Hypothetically, both erythrocyte 174 homeostasis and VVs could be linked to iron overload 19, 20 . It is noteworthy that association 175 between hemochromatosis-related functional variant in the HFE gene and primary VVs was 176 revealed in our previous candidate-gene study in ethnic Russian individuals 19 . 177
Searching for functional variants 178
Ensembl Variant Effect Predictor (VEP) 51 analysis identified one moderate-impact 179 missense variant rs2044693 in the PNO1 gene (in the locus tagged by rs2861819). SIFT and 180
PolyPhen tools predicted no damaging effect of this SNP on the protein function. Additionally, 181
we revealed 19 SNPs in regulatory regions (in loci tagged by rs9972656, rs2861819, 182 rs11135046, and rs7773004), and one synonymous variant rs1368298 in the EBF1 gene (in the 183 locus tagged by rs11135046). The full data is available in Supplementary table 5. 184
Testing for pleiotropy: VVs and gene expression 185
We used Summary data-based Mendelian Randomization (SMR) analysis followed by the 186 Heterogeneity in Dependent Instruments (HEIDI) 52 test to identify genes whose expression level 187 is associated with the same causal SNPs that affect the risk of VVs. The results are given in 188 Supplementary table 6. SMR/HEIDI analysis provided evidence for pleiotropic effects of 189 variants within rs3101725 and rs2861819 regions. In the first region, association was revealed 190 with the expression of long intergenic non-protein coding RNA 1184 (LINC01184) located in 191 close proximity to the SLC12A2 on the reverse strand. Changes in the SLC12A2 expression were 192 not associated with VVs in our tests. Interestingly, the previous study showed that disruption of a 193 bi-directional promoter between these genes altered the expression of both SLC12A2 and 194 LINC01184, while deletion of the third exon of LINC01184 affected only LINC01184 195 expression 36 . 196 In the locus tagged by rs2861819, our analysis identified four genes -PPP3R1, PLEK, 197 WDR92, and PNO1. It is likely that this region contains a strong eQTL that affects the 198 expression of nearby genes in different tissues and influences the risk of VVs. 199 It is important to note that SMR/HEIDI analysis does not distinguish pleiotropy from 200 causality. Therefore, we can hypothesize causal relationships between the expression level of 201 identified genes and the risk of VVs development. 202
Besides this, we found associations with expression levels of four genes within rs2911463 203 region (APRT, ZFPM1, RNF166, and PIEZO1) as well as with expression level of the TRIM38 204 gene located ~280 kb from rs7773004. However, statistically significant heterogeneity revealed 205 in the HEIDI test indicated that these associations were mediated by polymorphisms different 206 from those that alter VVs risk. 207
DEPICT analysis 208
Data-driven Expression Prioritized Integration for Complex Traits (DEPICT) framework 53 209 was used to conduct a gene set and tissue enrichment analysis as well as to provide additional 210 evidence for gene prioritization. Results of DEPICT analysis for SNP sets associated with VVs 211 at P < 5.0e-08 and P < 1.0e-05 are given in Supplementary tables 7 and 8, respectively. For the 212 first set, we identified a significant enrichment of the Mammalian Phenotype (MP) Ontology 213 terms "abnormal vasculogenesis" and "abnormal vascular development". When we relaxed 214 significance threshold of input SNPs to P < 1.0e-05, 22 MP terms were shown to be enriched 215 with additional 9 categories related to abnormal morphology of heart and vessels ("abnormal 216 blood vessel morphology", "abnormal vascular smooth muscle morphology", "failure of heart 217 looping", etc.). The remaining MP terms were associated with aberrant morphology of other 218 tissues and organs and disruption of embryonic development. Besides this, we observed 219 enrichment for several subnetworks of protein-protein interactions, including that for ENG 220 (major glycoprotein of the vascular endothelium, mutations in its gene cause multisystemic 221 vascular dysplasia), SMAD 2, 4, 6, 7 (transduce signals from TGF-beta family members), and 222
Notch4 (regulates arterial specification 54 ). 223
Tissue enrichment analysis revealed no statistically significant categories. 224 DEPICT gene prioritization tool provided 2 and 47 prioritized genes depending on the 225 level of statistical significance of the input SNPs (P < 5.0e-08 and P < 1.0e-05, respectively; 226 Supplementary tables 7 and 8). 227
Summary of gene prioritization 228
Basing on cumulative evidence from different analyses, we drew up a list of genes which 229 most likely account for the revealed associations and seem to be functionally relevant to VVs 230 development (Table 3 ). For two loci on chromosomes 2 and 5, we were unable to prioritize any 231 candidate gene. However, for the locus on chromosome 2, we advocate for the PPP3R1 gene 232 since it displayed the lowest P and the greatest effect size in the SMR test (P = 1.3e-22 and β = 233 120.0, Supplementary table 6) . Moreover, biological functions of PPP3R1 suggest its 234 involvement in VVs etiology (Table 2 ). In particular, it induces MCP-1 production, which was 235 shown to be enhanced in VVs 55,56 . Finally, a recent study demonstrated that expression of 236 PPP3R1 is increased in the venous tissue of VVs patients compared with veins of healthy 237 individuals (fold change = 1.5) 57 . 238
Testing for pleiotropy: VVs and other complex traits 239
SMR/HEIDI analysis revealed 31 traits that shared the same casual variants with VVs 240 (traits for this and further analyses were obtained from the GWAS-MAP database, see Methods 241 section for details). These SNPs were located in 5 out of 7 loci identified in our study ( Fig. 3 , 242 Supplementary table 10) . Variants within loci tagged by rs11121615 and rs3101725 showed 243 positive SMR beta coefficients (the same direction of effect) with predicted and fat-free mass of 244 both legs and a whole body as well as with basal metabolic rate, and negative coefficients 245 (opposed effects)with leg fat percentage as well as impedance of both legs and a whole body 246 (parameter negatively correlated with fat-free mass). Loci tagged by rs3101725 and rs7773004 247 comprised SNPs with pleiotropic effects on red blood cell erythrocyte distribution width 248 (negative beta). Locus tagged by rs7773004 was also related to numerous blood traits, such as 249 mean corpuscular haemoglobin concentration, mean platelet thrombocyte volume, and monocyte 250 and reticulocyte count. Three loci (rs11135046, rs28558138, and rs28558138) were linked to 251 blood pressure and hypertension with different SMR beta signs. Another interesting finding was 252 identification of positive SMR beta for associations with vascular/heart problems (rs28558138 253 locus), cellulitis (rs3101725 locus), forced viral capacity, and height size at age 10 (rs7773004 254 locus). Overall, our analysis revealed four main groups of traits: one cluster related mainly to 255 mass, one cluster involving mostly fat-and blood pressure-related traits, one cluster of blood-256 related traits linked only to rs7773004 locus, and one independent trait "red blood cell 257 erythrocyte distribution width" (Fig. 3) . 258
Genetic correlations 259
Genetic correlations between VVs in different datasets (discovery and replication cohorts, 260 etc.) are given in Supplementary table 1 
. A list of genetic correlation estimates (rg) between VVs 261
and 861 complex traits is presented in Supplementary table 11. Twenty five traits showed 262 statistically significant correlation with VVs with absolute values of rg ≥ 0.2. Correlation matrix 263 for this subset is displayed as a heatmap in Fig. 4 . We observed 5 main clusters: traits related to 264 the type of job, intelligence, and qualification; traits related to height and mass (including 265 predicted and fat-free mass of both legs); thrombosis-related traits; traits related to operations; 266 and traits related to pain (including leg pain and gonarthrosis) and health satisfaction. VVs trait 267 was closest to the thrombosis-related cluster (positive correlation). It was also positively 268 correlated with mass, operations, and pain-related traits as well as with lower levels of 269 qualification and heavy manual/walking/standing job. For traits with less prominent correlation 270 with VVs, we observed the same trend: pain and anthropometric traits (sitting and standing 271 height, BMI, mass, etc.) showed positive correlations, whilst higher levels of education -272 negative. Interestingly, negative correlation was observed with usual walking pace, and positive 273 with current smoking. 274
We calculated partial genetic correlations for the subset of 7 non-collinear traits with 275 |rg |≥ 0.2. Two traits -DVT and height size at age 10were shown to share common genetic 276 background with VVs after the adjustment for the remaining traits in the analyzed subset 277 ( Supplementary fig. 3 ). In other words, their shared genetic components were demonstrated to be 278 at least partially independent of other complex traits. Additionally, we estimated partial genetic 279 correlations between VVs, standing height, and weight. Both standing height and weight had 280 independent genetic components shared with VVs ( Supplementary fig. 4 ). 281
Hypothesis-free search for causal relationships 282
We applied a 2-sample Mendelian randomization (2SMR) 58 strategy to infer causal 283 relationships between a broad range of "exposure" phenotypes and VVs as an outcome. In total, 284 39 complex traits were shown to be potential causative factors. Although only genome-wide 285 associated SNPs from exposure GWAS were selected as instrumental variables, we did not 286 require these loci to be replicated. Nevertheless, we checked the stability of our tests with regard 287 to instruments selection by performing the robustness analysis. This test along with the Steiger 288 test 59 for the correct direction of effect underpinned the exclusion of 2 out of 39 traits 289
( Supplementary table 12 ). Further, we assessed violations of MR assumption of absence of 290 horizontal pleiotropy (influence of genetic instruments on the outcome only through the 291 exposure, also known as "exclusion-restriction criterion") by means of sensitivity analyses 58 . We 292 did not observe a statistically significant intercept in MR-Egger regression for any trait. 293 However, only a small proportion of traits showed symmetry in Funnel plots and had no 294 heterogeneity in causal effects amongst instruments. This provides evidence that, for the 295 majority of traits, at least some of the selected instruments exhibit horizontal pleiotropic effects. 296 Such traits mainly involved several hundred genome-wide SNPs that made leave-one-out 297 analysis also uninformative. In order to correct for horizontal pleiotropy, we applied a 298 straightforward approach having excluded all instrumental variables associated with VVs at the 299 level of statistical significance higher than 0.01. Our correction led to symmetry in 26 out of 33 300 asymmetrical Funnel plots and eliminated heterogeneity in causal effects for 28 out of 34 traits, 301 although 6 traits lost the statistical significance of 2SMR coefficients (Supplementary fig. 5 -42, 302 Supplementary table 12 ). Removing potential sources of heterogeneity also reduced absolute 303 values of 2SMR beta for all the corrected phenotypes. A graphical representation of our results, 304
including 25 causal inferences that we consider the most reliable, is shown in Fig. 5 . Twenty one 305 traits were related to anthropometry and included standing and sitting height, weight, hip and 306 waist circumference, fat-free, predicted, and fat mass of legs and arms, etc. One trait was a 307 spirometry measurement associated with pulmonary function. Nonetheless, since it is positively 308 correlated with height, we suppose that it has no independent effect on VVs development. 309
Similarly, the reverse association between malabsorption/coeliac disease and VVs could actually 310 be induced by a weight loss as one of the complications of these conditions. Moreover, although 311 this trait has passed all the necessary tests, we avoid making strong claims about its causality 312 since it was self-reported and involved only ~1,500 cases. 313
All the above mentioned traits were derived from the Neale Lab repository and therefore 314 had about 80% sample overlap with VVs dataset obtained from the Gene ATLAS. Shared 315 participants between the "exposure" and the "outcome" GWAS can cause bias in the Mendelian 316 randomization analysis when weak instruments are selected 60 . In our study, this limitation was 317 partially mitigated by using only strong instruments associated with exposure traits at a high 318 level of statistical significance (P < 1.0e-08). In order to fully overcome the problem and confirm 319 our results, we searched for independent GWAS and performed a replication analysis. Data were 320 obtained for height, weight, waist circumference, and body fat percentage. Only height reached 321
Bonferroni-corrected level of statistical significance and remained significant after the correction 322 for pleiotropy (2SMR P < 1.0e-07, Supplementary table 13 ). However, null results for other 323 traits could be explained by a limited power of the analysis. For example, sample size for weight 324 was 4.5 times smaller than in the Neale Lab study. 325
Finally, the remaining two traits from the "reliable" set were plasma levels of MHC class I 326 polypeptide-related sequence B protein and CD209 antigen. These phenotypes were not UK 327
Biobank traits, therefore our results could not be confounded by a sample overlap. 328
Discussion 329
In the present study, we utilized freely available GWAS summary data to unravel the 330 genetic underpinnings of VVs of lower extremities. Lack of individual-level data made us be as 331 rigorous as possible to avoid false positive discoveries, so we skimmed off the most apparent 332 evidence. Nevertheless, as far as we are aware, our study is the largest and the most 333 comprehensive study of VVs genetics to date. Beyond that, the availability of GWAS results 334 makes our research fully reproducible. 335
We identified and replicated 7 susceptibility loci that explain 10% of the SNP-based 336 heritability, and prioritized the most likely causal genes (Fig.2, Tables 1-3 ). Overall, SNP 337 heritability on the liability scale was estimated at ~28 % assuming the disease prevalence of 20-338 30%. Almost 40% of the variance explained by our top SNPs was attributable to the 339 polymorphism in the CASZ1 gene involved in blood vessel development. This strong signal has 340 previously been revealed by "23andMe" 12 and subsequently replicated in our own sample of 341 ethnic Russian individuals 10 . An especially interesting finding, in our opinion, is a novel 342 association of VVs with SNPs in a recently discovered PIEZO1 gene. PIEZO1 encodes a 343 pressure-activated ion channel which senses shear stress and controls vascular architecture 27 . 344
Mice embryos lacking functional Piezo1 exhibit defects in vascular remodeling and die at 345 midgestation 61 . Other prioritized genes were PPP3R1, EBF1, STIM2, and HFE. The latter gene 346 has been linked to the risk of VVs in our recent candidate-gene study 19 . Meanwhile, we could 347 not prioritize any gene in the locus tagged by rs3101725. On the one hand, this region contains 348 two genes (SLC12A2 and FBN2) that could play a role in varicose transformation, and on the 349 other hand, the causal polymorphism was shown to be eQTL for a nearby non-protein coding 350 RNA LINC01184 with unknown function. The revealed genes can be considered as good 351 candidates for future follow-up functional studies. It is noteworthy that SLC12A2, FBN2, STIM2, confirmed known epidemiological associations between VVs and DVT 1,16 as well as standing 360 job 1,64,65 , rough labour 65,66 , and lower levels of education 64 (Fig.4, Supplementary table 11) . 361 Shared familial susceptibility with venous thromboembolism has already been shown by Zöller 362 et al 67 . Here we demonstrate that DVT and VVs share specific genetic components which are 363 independent from other factors such as obesity or number of operations (Supplementary fig. 3 ). 364
Since none of the top GWAS hits were related to thrombosis, we can conclude that SNPs with 365 less prominent associations are responsible for this genetic overlap. On the contrary, albeit 366 several identified loci were also associated with blood pressure/hypertension and red blood cell 367 traits, including mean corpuscular hemoglobin concentration (Table 2, Fig. 3 ), we found no 368 evidence for genetic correlation between VVs and these traits. We can therefore attribute these 369 effects only to pleiotropy. Intriguingly, we observed small, but significant genetic overlap with 370 smoking (rg = 0.16). Smoking is considered only as suggestive risk factor for VVs since 371 epidemiological studies have mainly shown no association with this habit 1,64,66,68 . Other novel 372 interesting findings include genetic links with prospective memory and fluid intelligence 373 (negative correlation), pain (knee pain, pain all over the body, neck or shoulder pain, and leg 374 pain on walking), usual walking pace, and gonarthrosis. 375
Further, we obtained strong evidence for association between VVs and anthropometric 376 traits such as weight, height, waist and hip circumference. We not only observed genetic 377 correlations (Fig. 3, Fig. 4, Supplementary tables 10, 11 ), but also demonstrated these traits to be 378 causative factors for VVs development (Fig. 5, Supplementary table 12 ). It is important to note 379 that genetic overlap and causal relationships were inferred for both fat and fat-free mass. Thus, 380 we can speculate that increased weight is a risk factor for VVs regardless of whether it was 381 caused by excess body fat or a large mass of other tissues. According to some theories, 382 association between overweight and VVs can be explained by greater concentrations of 383 circulating estrogens or even by a confounding effect of parity 1 . Although this can be true, our 384 results suggest that the cause may also be an increase in mass per se. Moreover, we found that 385 height has common genetic component with VVs independent from weight and other traits 386 (Supplementary fig. 4 ) and is also causally related to VVs (Fig. 5 ). Causal inference was 387 additionally confirmed using an independent dataset ( Supplementary table 13 ). This is in 388 agreement with the results of the Edinburgh Vein Study that has shown a significant relationship 389 between increasing height and VVs 64 . However, the majority of epidemiological studies to date 390 have been focused only on BMI and did not consider height or other body characteristics. 391
Notably, the formula for BMI contains the square of height in the denominator. It is possible that 392 the impact of height underlies the inconsistency in the results, when some studies show a 393 positive association between BMI and VVs, while others reveal no effect 1 . We therefore 394 recommend that future epidemiological studies collect and analyze data on height and weight 395 along with data on BMI. 396
Last but not least, we detected the causal effect of plasma levels of two proteins -MHC 397 class I polypeptide-related sequence B protein (MICB) and CD209 antigen. Both molecules are 398 involved in innate and adaptive immunity. MICB is a ligand for the activating receptor NKG2D 399 present on the surface of natural killer and some other immune-related cells. CD209, also known 400 as DC-SIGN, is a C-type lectin receptor expressed on dendritic cells and macrophages. In our 401 study, Mendelian randomization analysis for CD209 was performed using two genetic 402 instruments -rs505922 and rs8106657 identified by Suhre et al 69 . The first SNP is located in the 403 ABO gene responsible for ABO blood group determination. Allele rs505922 C tags non-O group 404 and is in linkage disequilibrium with the allele A of the neighboring SNP rs507666 (D' = 1.00, r 2 405 = 0.39), which was found to be the top variant associated with VVs in the "23andMe" GWAS 12 406
This association was validated in our previous study using data from UK Biobank 10 . At the same 407 time, rs505922 explains nearly 40% of the variability of the plasma CD209 concentration (our 408 estimate based on the published data 69 ) with the allele C being linked to higher levels of CD209. 409
It is tempting to speculate that association between the ABO gene polymorphisms and VVs as 410 well as between VVs and blood group A 70 is mediated by this protein. consent from the UK Biobank study. Associations were adjusted for sex and the first 10 principal 440 components from the UK Biobank sample QC file. We also adjusted the data for body mass 441 index and deep venous thrombosis using GWAS summary statistics for these traits downloaded 442 from the same resource, and corrected the results for potential confounding using the intercept 72 443 as a genomic control inflation factor λ. Details are given in Supplementary Methods. 444 A replication stage was performed by a reverse inverse-variance weighted meta-analysis 445 that yielded genetic association data for 71,256 individuals (Fig. 1 ). For these purpose, we 446 derived summary statistics for 408,455 UK Biobank participants (10,861 cases and 397,594 447 controls) from the Gene ATLAS database 14 (http://geneatlas.roslin.ed.ac.uk/) and used these data 448 as a "minuend" dataset. A detailed description of our approach with statistical processing is 449 presented in Supplementary Methods, in the study of Deng et al. 18 , and in our manuscript 450 deposited on bioRxiv 17 . Data provided by the Gene ATLAS project were obtained for a cohort of 451 both related and unrelated individuals of white British descent. The associations were calculated 452 using Mixed Linear Models with adjustment for age, age 2 , sex, array batch, UK Biobank 453 Assessment Center, and the leading 20 genomic principal components as computed by UK 454
Biobank. Details of this study including QC criteria have been reported previously 14 . In brief, 455 they excluded individuals with missing or conflicting data, non-biallelic variants, and SNPs with 456 MAF <0.01% and/or the Hardy-Weinberg equilibrium P < 1.0e-50. The Gene ATLAS contains 457 information for over 30 million variants. In our analysis, we focused on 10,829,469 SNPs that 458 overlap the Neale Lab SNP set. 459
Conditional analysis 460
Regional association plots were generated with LocusZoom tool (http://locuszoom.org/) 461 for regions within 250 kb from the lead SNP. Only replicated loci were analyzed. Conditional 462 and joint (COJO) analysis was carried out by a summary statistics-based method described by 463 Yang et al. 73 Calculations were performed using the GCTA software 74 . LD matrix was computed 464 with PLINK 1.9 software (https://www.cog-genomics.org/plink2) using 1000 Genomes data for 465 503 European individuals (http://www.internationalgenome.org/data/). We claimed the presence 466 of one independent signal per locus if none of the polymorphisms except the lead SNP passed 467 the significance threshold of P = 5.0e-08. 468 469
Literature-based functional annotation 470
We used regional association plots to identify genes located within associated loci. These 471 genes were further queried for potential involvement in the processes relevant to VVs 472 pathogenesis. For each gene, we scanned an Online Catalog of Human Genes and Genetic 473
Disorders
(OMIM, https://www.omim.org/), the NCBI Gene 474 (https://www.ncbi.nlm.nih.gov/gene), and the Pubmed database to inquire into their biological 475 functions. Furthermore, we interrogated whether other hypothetical varicose-related traits were 476 associated with these genes according to previously published GWAS. The Pubmed search was 477 performed using the gene name as a keyword as well as combinations of the gene name and 478 "GWAS", or "genome-wide association study", or "varicose", or "venous", or "vascular". The 479 information obtained was used for the literature-based gene prioritization. 480
Additionally, we used a PhenoScanner 75 tool 481 (http://www.phenoscanner.medschl.cam.ac.uk/phenoscanner) to make a list of complex traits 482 associated at P < 5.0e-08 with lead SNPs or other polymorphisms in high LD (r 2 ≥ 0.7) with lead 483 variants. 1000 Genomes-derived polymorphisms served as proxies for the analysis. 484
VEP analysis 485
For the VEP 51 analysis, we used a set of SNPs within replicated regions associated with 486 VVs at P ≤ T, where log10(T) = log10(Pmin) + 1, and Pmin is a P-value for the strongest association 487 per locus (±250 kb from the independent hit). Analysis was performed using software available 488 online (https://www.ensembl.org/info/docs/tools/vep/index.html). 489
SMR/HEIDI analysis 490
SMR/HEIDI 52 approach was used to test for potential pleiotropic effects of identified loci 491 on VVs and other complex traits including gene expression levels in certain tissues. SMR 492 analysis provides evidence for pleiotropy, but is unable to define whether both traits are affected 493 by the same underlying causal polymorphism. The latter is specified by a HEIDI test that 494 distinguishes pleiotropy from linkage disequilibrium. Summary statistics for gene expression 495 levels was obtained from Westra Blood eQTL 76 (peripheral blood, 496 http://cnsgenomics.com/software/smr/#eQTLsummarydata) and the GTEx 77 database (44 tissues, 497 https://gtexportal.org). VVs summary statistics was obtained from the Gene ATLAS database 498 since it enables the maximum statistical power due to the greatest sample size. At the same time, 499
VVs in this GWAS is completely correlated at a genetic level with VVs in our discovery dataset 500 (rg = 1.00, Supplementary table 1) . Summary statistics for other complex traits was derived from 501 the GWAS-MAP database (see below). 502
Nominal P for SMR test was set at 2.63e-05 (0.05/1,898, where 1,898 is the total number 503 of probes for the gene expression analysis) and 1.89e-06 (0.05/7*3,787, where 7 is the number of 504 loci and 3,787 is the total number of non-VVs traits in GWAS-MAP). For HEIDI analysis in a 505 gene expression study, we used a conservative threshold of P = 0.01 (P < 0.01 corresponds to the 506 rejection of pleiotropy hypothesis). For HEIDI in a complex traits analysis, we implemented a 507 less conservative threshold of P = 0.001 since the number of independent test was much higher. 508
Details of data processing are given in Supplementary Methods. 509
DEPICT analysis 510
DEPICT analysis was performed using DEPICT 53 software version 1.1, release 194 511 (https://data.broadinstitute.org/mpg/depict/) with default parameters. GWAS summary statistics 512 was obtained from the Gene ATLAS database. We employed DEPICT for both genome-wide 513 significant SNPs (P < 5.0e-08) as well as for loci associated with VVs at P < 1.0e-05. As in 514 previous analyzes, we defined locus as ±250 kb from the lead SNP. The major histocompatibility 515 complex (MHC) region was eliminated. Significance threshold was set at FDR < 0.05. 516
GWAS-MAP platform 517
GWAS-MAP platform integrates a database which was created to study cardiovascular 518 diseases and contains summary-level GWAS results for 123 metabolomics traits, 1,206 519 circulating proteins, 2,419 complex traits from the UK Biobank, and 8 traits related to coronary 520 artery disease, myocardial infarction and their risk factors. We additionally added 6 VVs-related 521 traits analyzed in the present study (our discovery and replication datasets; the Gene ATLAS 522 data for VVs; and the Neale Lab data for VVs, BMI, and DVT) as well as 33 traits from the 523 Gene ATLAS database that we supposed to be biologically relevant to VVs. Description of all 524 3,795 traits is provided in Supplementary table 9. GWAS-MAP platform contains embedded 525 software for LD Score regression 72 , 2SMR analysis (MR-Base package 58 ), and our 526 implementation of SMR/HEIDI analysis 52 . Further details are given in Supplementary methods. 527
Genetic correlations 528
Genetic correlations (rg) between VVs and other complex traits were calculated using 529 LDSC software (https://github.com/bulik/ldsc/). We applied a cross-trait LD Score regression 530 technique as previously described by Bulik-Sullivan et al. 78 This method requires only GWAS 531 summary statistics and is not biased by a sample overlap. We analyzed 861 heritable non-VVs 532 traits from the GWAS-MAP database. Only traits with a total sample size of ≥ 10,000 and ≥ 1 533 million SNPs tested were included in the analysis. GWAS summary statistics for VVs was 534 obtained from the Gene ATLAS database. Statistical significance threshold was set at 1.16e-05 535 (0.01/861). For 25 traits that passed this threshold with |rg| ≥ 0.2, we calculated a matrix of 536 genetic correlations. Partial genetic correlations were estimated using the inverse of the genetic 537 correlation matrix. Significance threshold was set at 3.1e-05 (0.01/325, where 325 is the number 538 of pairwise combinations). For partial genetic correlations between VVs, standing height, and 539 weight, nominal P was set at 3.3e-03 (0.01/3). Clustering and visualization was performed by the 540 "corrplot" package for the R language (basic "hclust" function). Further details are provided in 541 Supplementary Methods. 542
2SMR analysis 543
Casual relationships between 2,221 non-VVs phenotypes ("exposures") from the GWAS-544 MAP database and VVs ("outcome") were assessed by 2-sample Mendelian randomization 545 (2SMR) as previously described by the MR-Base collaboration 58 (http://www.mrbase.org/). All 546 the details of our protocol are given in Supplementary Methods. Binary traits with the number of 547 cases or controls less than 1000 were not included in the study. GWAS summary statistics for 548 VVs was obtained from the Gene ATLAS database. Analysis was performed on the GWAS-549 MAP platform. Two 2SMR approaches were used: an inverse variance weighted meta-analysis 550 of Wald ratios (IVW) and MR-Egger regression. The nominal P was set at 1.1e-05 551 (0.05/2*2,221, where 2 is the number of approaches). For traits that passed either IVW or Egger test, we performed the Steiger test 59 for identifying the correct direction of effect, and 553 conducted the robustness analysis (our own approach). Traits that passed all the analyses were 554 then subjected to sensitivity tests 58 , that included assessing heterogeneity in causal effects 555 amongst instruments, horizontal pleiotropy test (based on the intercept in MR Egger regression), 556 leave-one-out analysis, and Funnel plots inspection. The nominal P for the Steiger test was set at 557 2.3e-05 (0.05/2,221), and for the robustness analysis, horizontal pleiotropy test, and 558 heterogeneity analysisat 1.3e-03 (0.05/38, where 38 is the number of traits that passed both 559 2SMR analysis and the Steiger test). Leave-one-out and Funnel plots were examined manually. 560
Sensitivity analyses revealed the presence of horizontal pleiotropy for the majority of traits. To 561 correct for this confounder, we omitted all instrumental variables associated with VVs with 562 P < 0.01, and then repeated IVW 2SMR and sensitivity analyses. Additionally, for the resulting 563 set of traits, we searched for independent GWAS in the MR-Base database 58 We express our gratitude to the Neale Lab and the Gene ATLAS projects for providing GWAS 582 summary statistics for UK Biobank traits. We sincerely thank Yurii Aulchenko for valuable 583 discussion. We gratefully acknowledge Denis Gorev, Eugene Pakhomov, and Anna Torgasheva 584 who contributed to the development of the GWAS-MAP platform. We acknowledge Eugene 585
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Materials & Correspondence 598
Correspondence and requests for materials should be addressed to Alexandra S. Shadrina In the discovery stage, we used GWAS summary statistics for VVs provided by the Neale Lab 787 and adjusted it for two potential confoundersbody mass index (BMI) and deep venous 788 thrombosis (DVT). GWAS data for these traits was also obtained from the Neale Lab database. 789
In order to validate the revealed association signals, we generated a replication cohort by means 790 of reverse meta-analysis using data from by the Gene ATLAS (larger sample size) and the Neale 791
Lab (smaller sample size) databases. VVs traits in all datasets including our simulated replication 792 sample were highly genetically correlated with each other ( Supplementary table 1 ). For 7 793 replicated loci, we performed a functional annotation analysis. Other analyses were conducted 794 using the Gene ATLAS data since it enables to achieve the highest statistical power and is 795 genetically equivalent to our discovery dataset (rg = 1.00). Color depicts the sign and the magnitude of SMR beta coefficient. Negative sign (red) means 806 opposed effects, and positive sign (blue) means the same direction of effect. Traits that passed 807
both SMR and HEIDI test are marked with an asterisk. Prioritized genes in loci are shown in 808
brackets. Full names of traits as indicated in the Neale lab and the Gene ATLAS databases are 809
given in Supplementary table 14 T/G 0.54 -0.0025 0.0003 5.9e-13 -0.0025 0.0003 3.7e-13 1.1e-12 -4.13 3.6e-05 0.9 rs28558138 4: 26818080 C/G 0.42 -0.0024 0.0004 1.8e-11 -0.0024 0.0004 1.3e-11 3.2e-11 -6.39 1.7e-10 1.1 rs7773004 6: 26267755 G/A 0.49 -0.0023 0.0003 5.2e-11 -0.0023 0.0003 6.4e-11 1.5e-10 -3.05 0.002 0.6 rs7856039 9: 118385117 C/T 0.67 0.0024 0.0004 5.7e-11 0.0024 0.0004 8.1e-11 1.9e-10 0.10 0.92 ̶ rs9880192
3: 128297569 C/G 0.41 -0.0023 0.0004 8.0e-11 -0.0023 0.0004 8.7e-11 2.0e-10 -2.03 0.04 ̶ rs192647746 4: 182760366 G/A 0.001 0.0336 0.0054 4.5e-10 0.0333 0.0052 1.2e-10 2.9e-10 -1.01 0.31 ̶ rs12625547 20: 50154647 G/T 0.17 -0.0029 0.0005 1.2e-10 -0.0029 0.0005 1.3e-10 2.9e-10 -2.18 0.03 ̶ rs236530
17: 68217471 T/C 0.75 -0.0026 0.0004 1.8e-10 -0.0026 0.0004 1.4e-10 3.2e-10 -2.84 0.005 ̶ rs2241173 17: 70028445 G/A 0.58 -0.0022 0.0004 4.5e-10 -0.0022 0.0004 4.4e-10 9.7e-10 -1.84 0.07 ̶ rs73107980 12: 48187601 T/C 0.24 0.0025 0.0004 1.7e-09 0.0025 0.0004 1.4e-09 2.8e-09 1.65 0.10 ̶ rs10084824 4: 89515141 A/C 0.01 0.0100 0.0018 4.8e-08 0.0101 0.0018 1.2e-08 2.3e-08 -1.75 0.08 ̶ rs6062619 20: 62683002 G/A 0.27 -0.0022 0.0004 2.0e-08 -0.0022 0.0004 1.4e-08 2.6e-08 -2.80 0.005 ̶ rs1936800 6: 127436064 T/C 0.53 -0.0019 0.0003 2.0e-08 -0.0020 0.0003 1.9e-08 3.6e-08 -0.31 0.76 ̶ rs11693897 2: 45933993 T/C 0.004 0.0148 0.0029 3.3e-07 0.0149 0.0027 3.3e-08 6.2e-08 -0.94 0.34 ̶ rs247749
5: 76296735 C/T 0.31 0.0021 0.0004 5.5e-07 0.0021 0.0004 3.9e-08 7.3e-08 1.78 0.07 ̶ rs1061539
6: 29937555 C/T 0.83 -0.0025 0.0005 4.0e-08 -0.0025 0.0005 4.8e-08 8.9e-08 -2.69 0.007 ̶ BMI, body mass index; DVT, deep venous thrombosis; EAF, effect allele frequency; SE, standard error; SNP, single nucleotide polymorphism * Chromosome: position on chromosome according to GRCh37.p13 assembly † Effect allele/reference allele ‡ P-value corrected for the genomic inflation factor § Proportion of SNP-based heritability explained by the variant *Chromosome: position on chromosome according to GRCh37.p13 assembly † Calculated based on regional association plots generated with LocusZoom tool (http://locuszoom.org/, Supplementary fig.1 ) ‡ This locus contains two independent association signals. SNP rs9972645 that tags the second signal is also located in the PIEZO1 gene
